2020
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: e000341. PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitorsOverall survivalMetastatic melanomaPrimary tumorLocal therapyCutaneous melanomaAnti-PD-1 antibodyAggressive multidisciplinary approachCutaneous primary tumorPrimary tumor histologyMedian overall survivalSingle institutional experienceRare melanoma subtypeMedian OSMetastatic diseaseProgressive diseaseAcral skinComplete responsePD-1PD-L1Uveal tractTumor histologyCombination therapyCTLA-4Longer survival
2015
Melanoma: Clinical Presentations
Kibbi N, Kluger H, Choi JN. Melanoma: Clinical Presentations. Cancer Treatment And Research 2015, 167: 107-129. PMID: 26601860, DOI: 10.1007/978-3-319-22539-5_4.Peer-Reviewed Original ResearchConceptsNon-cutaneous lesionsUpper gastrointestinal mucosaMalignant skin lesionsGenital mucosaUveal tractClinical presentationDistant metastasisCutaneous lesionsPattern of spreadTypical presentationGastrointestinal mucosaSkin lesionsOral cavityMucosal surfacesMalignant cellsMelanomaRed lesionsLesionsRegional spreadBasal layerMucosaMelanocytesPresentationLeptomeningesMetastasis